News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
81
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2600
|
|
Created
|
03/29/06
|
Type
|
Free
|
| Moderators | |||
http://www.stemcellinnovations.com/
Company Information:
11222 Richmond Ave., Suite 180
Houston, TX 77082-2646
USA
Phone +1 281 679 7900 / ext. 19
Fax +1 281 679 7910
Email info@stemcellinnovations.com
CIK
0000351532
Stem Cell Innovations (SCI) intends to become the global leader in human cell based drug discovery & development. SCI has laboratories and offices in Scotch Plains, N.J., Houston, TX and in Leiden, the Netherlands.
SCI's core technology focuses on developing, growing, and manipulating human cells in the laboratory using proprietary technology. By growing pure cultures of individual cell types, SCI is currently developing a broad array of human primary cell models as powerful research tools that can form the basis of therapeutic breakthroughs.
SCI has established several human pluripotent stem cell lines from fetal gonadal tissue using defined conditions. These PluriCellTM lines have been established directly onto tissue culture plastic without the use of feeder layers or conditioned medium. In addition to the PluriCell technology SCI has already established in vitro hepatocyte screening, kits, compositions, and services for compound toxicity testing, ACTIVTox® and PREDICTIVToxTM.
PluricellsTM & Derivatives ACTIVTox® PREDICTIVToxTM Endogenous Protein Production
Founding mode: Merger of Amphioxus Cell Technologies with Interferon Sciences
Management:
http://www.stemcellinnovations.com/about/management_team.php
Recent News:
http://www.stemcellinnovations.com/news/index.php?news
Filings:
Transfer Agent:
Computershare Investor Services LLC
2 North LaSalle Street
Chicago 60602
Share Structure:
Outstanding Shares
2,844,387,312 as of Jan. 13, 2010
Authorized Shares
20,000,000,000 as of Jan. 13, 2010
Stem Cell Innovations offers commercial partners access to its high-end human cell technologies and expertise through fee-for-service activities, collaborative partnerships and selective out-licensing. In addition, SCI is interested in exploring research alliances with academic and industrial partners as well as patient foundations in several therapeutic areas.
Current partners include:
ACTIVTox® (Powerpoint Presentation [2004])
http://www.toxicology.org/isot/RC/ncac/symposia_files/Spring2004Kelly.pps
Do your own DD & trade smart
Founding mode: Merger of Amphioxus Cell Technologies with Interferon Sciences
Current report filing (8-K)
Date : 01/13/2010 @ 3:00PM
Source : Edgar (US Regulatory)
Stock : - (SCLL)
http://ih.advfn.com/p.php?pid=nmona&cb=1263413430&article=41095210&symbol=NO^SCLL
Stem Cell Innovations, Inc., (SCLL.PK) wishes to update its shareholders on various aspects of the company over the past year.
Our human embryonic germ cell technology has matured substantially. This work was significantly more difficult than originally anticipated but has resulted in a series of interesting and useful observations that will fill in several missing pieces in human stem cell biology. These observations are currently being finalized and assembled into a form suitable for publication in scientific journals. We anticipate the publication of several such scientific papers over the coming year and these advances will enable us to pursue the application of our technology to drug discovery, liver disease and cancer. It is important to note that this technology is completely separate from standard human embryonic stem cells and comprises a unique and valuable intellectual property.
As a result of the shareholder vote that was held in August, the number of authorized shares was expanded to 20 billion. There are currently 2,844,387,312 shares issued and outstanding. The financing by Margie Chassman that was announced in conjunction with the vote has been completed. These funds, along with income from ongoing and new contract research, should enable the Company to put a program in place over the next six to nine months that will enable us to become listed again on the Bulletin Board and become current with our filings. It is important to the Company to be as transparent as possible within the confines of this difficult financial environment and we are working diligently to achieve this.
Last updated 3.6.2010
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp
